Lopez-Pedreda et al., in a study involving 42 patients with APS treated with 20 mg of fluvastatin a day for 1 month, found significant inhibition of monocyte protein activator receptors 1 and 2, as well as reduced expressions of VEGF and Flt1, mediated by the inhibition of p38 MAPK and NFκB/Rel DNA-binding activity [130]. This evidence concerns the gene VEGFA and autoimmune polyendocrinopathy.